Chronic 3,4-methylenedioxymethamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine1C receptor gene expression in the rat hippocampus.
Both glucocorticoids and serotonin have been implicated in the regulation of mood and neuroendocrine control. In this study we have examined the effects of the psychomotor stimulant, 3,4-methylenedioxymethamphetamine on corticosteroid and 5-hydroxytryptamine receptor subtype gene expression within the hippocampal formation using in situ hybridization histochemistry. Animals were injected subcutaneously with 3,4-methylenedioxymethamphetamine (20 mg/kg) twice daily for four days. Two weeks following this dosage regimen, shown to markedly reduce 5-hydroxytryptamine terminals, both glucocorticoid receptor and mineralocorticoid receptor messenger RNA expression were significantly decreased (30-47% fall) in the granule cells of the dentate gyrus and pyramidal cells of CA1-CA4 fields of Ammon's horn, but not in parietal cortex neurons. In the same rats, 5-hydroxytryptamine1C receptor messenger RNA expression was significantly increased in CA3 pyramidal neurons (133% rise), but neither 5-hydroxytryptamine1A or 5-hydroxytryptamine2 receptor messenger RNA levels were altered in any dorsal hippocampal subfield. 3,4-Methylenedioxymethamphetamine treatment was associated with modest hypersecretion of coricosterone during the diurnal nadir, without other peripheral evidence of chronic glucocorticoid excess (unchanged thymic and adrenal weights and corticosterone-binding globulin levels). These results emphasize the importance of the serotonergic innervation in maintaining hippocampal corticosteroid receptor gene expression. It is suggested that 5-hydroxytryptamine1C receptors may be involved in mediating the effects of serotonin on hippocampal glucocorticoid receptor and mineralocorticoid receptor expression and perhaps mood.
University of Edinburgh, Department of Medicine, Western General Hospital, U.K.
J L
JL
Yau
P A
PA
Kelly
J
J
Sharkey
J R
JR
Seckl
D000818:Animals; D001345:Autoradiography; D003345:Corticosterone / Q000097:blood; D015870:Gene Expression / Q000187:drug effects*; D006624:Hippocampus / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism*; D017403:In Situ Hybridization; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D017374:Paroxetine / Q000493:pharmacokinetics; D017966:Pyramidal Cells / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000096:biosynthesis* / Q000235:genetics; D018161:Receptors, Mineralocorticoid / Q000096:biosynthesis* / Q000235:genetics; D011985:Receptors, Serotonin / Q000096:biosynthesis* / Q000235:genetics
D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D011985:Receptors, Serotonin; D017374:Paroxetine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D003345:Corticosterone